Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Células CAR-T alogénicas P-MUC1C-ALLO1 en el tratamiento de sujetos con tumores sólidos avanzados o metastásicos

2 de noviembre de 2026 actualizado por: Poseida Therapeutics, Inc.

Un estudio de fase 1 de escalamiento de dosis y cohorte ampliada de P-MUC1C-ALLO1 en sujetos adultos con tumores sólidos avanzados o metastásicos

A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.

Descripción general del estudio

Descripción detallada

This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.

Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

180

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Irvine, California, Estados Unidos, 92868
        • University of California, Irvine Medical Center
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars Sinai Medical Center
      • San Diego, California, Estados Unidos, 92037
        • University of California, San Diego
      • San Francisco, California, Estados Unidos, 94143
        • University of California, San Francisco
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Sarah Cannon Research Institute at HealthONE
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Westwood, Kansas, Estados Unidos, 66205
        • University of Kansas Cancer Center
      • Wichita, Kansas, Estados Unidos, 67214
        • Cancer Center of Kansas
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Dana Farber Cancer Institute
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • University of Nebraska Medical Center
    • New York
      • The Bronx, New York, Estados Unidos, 10467
        • Montefiore Medical Center
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • MD Anderson Cancer Center
      • San Antonio, Texas, Estados Unidos, 78229
        • NEXT Oncology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Males or females, Subjects ≥18 years with life expectancy >3 months
  • Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer
  • Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
  • Must have adequate vital organ function within pre-determined parameters
  • Must have archived tumor tissue available or consent to a biopsy collection
  • Must be willing to practice birth control
  • Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration
  • Must have recovered from toxicities due to prior therapies

Exclusion Criteria:

  • Has inadequate venous access
  • Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
  • Is pregnant or lactating
  • Has a history of or active autoimmune disease
  • Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
  • Has an active systemic (viral, bacterial, or fungal) infection
  • Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia
  • Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
  • Has received anticancer medications within 2 weeks of the time of initiating lymphodepletion
  • Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study
  • Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study
  • Has known CNS metastases or symptomatic CNS involvement
  • Has a history of significant liver disease or active liver disease
  • Has a history of known genetic predisposition to HLH/MAS
  • Has received anti-cancer monoclonal antibody therapy within 4 weeks of initiating LD therapy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)
  • Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)
  • Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
  • Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)
  • Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1)
  • Single ascending A1 dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E)
  • Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F)
  • Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M)
  • Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.
  • Rimiducid may be administered as indicated.

P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Rimiducid (safety switch activator) may be administered as indicated.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
Periodo de tiempo: Baseline through Day 28

Number of subjects with a dose limiting toxicity (DLT)

Baseline through Day 28
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
Periodo de tiempo: Baseline through 15 years

Frequency and severity of adverse events

Baseline through 15 years
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
Periodo de tiempo: Baseline through 15 years

According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, secondarily Immune Response Evaluation Criteria in Solid Tumors (iRECIST): Overall Response Rate (ORR)

Baseline through 15 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Simon Heidegger, M.D., Lead Medical Director, Oncology, Genentech Research Early Development

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de febrero de 2022

Finalización primaria (Estimado)

1 de abril de 2039

Finalización del estudio (Estimado)

1 de abril de 2039

Fechas de registro del estudio

Enviado por primera vez

3 de febrero de 2022

Primero enviado que cumplió con los criterios de control de calidad

3 de febrero de 2022

Publicado por primera vez (Actual)

14 de febrero de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • P-MUC1C-ALLO1-001

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir